• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Lazard

Lazard

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials

    Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials

  2. Lazard Closes One Fund, Opens Another

    Plus, Wasatch's new purchase, SEC's million-dollar distribution, and more.

  3. Our Outlook for Financial-Services Stocks

    The financial sector is fully valued despite global uncertainties.

  4. Wilmington Trust Names Leader to Grow New York Practice

    Former Lazard Wealth Management executive Sharon Klein joined Wilmington Trust to build its growing practice in the New York metro area.

  5. Pick-and-Shovel Plays for Rising Mergers and Acquisitions

    Investment banks are a good way to play the new M&A cycle.

  6. Blurred Lines for Funds a Mixed Blessing for Investors

    Pushing against borders allows more freedom and choice but complicates selection and evaluation.

  7. Blurred Lines for Funds a Mixed Blessing for Investors

    Pushing against borders allows more freedom and choice but complicates selection and evaluation.

  8. Where Are the Opportunities in Emerging Markets?

    Culling ideas from top emerging-markets fund managers.

  9. Three Financials Experts Pick through the Wreckage

    Fund managers spotlight winners and losers as the sector reshuffles.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.